Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

1.01
+0.129314.68%
Post-market: 1.030.0200+1.98%19:59 EDT
Volume:4.93M
Turnover:5.08M
Market Cap:85.62M
PE:-0.40
High:1.12
Open:0.9200
Low:0.9200
Close:0.8807
52wk High:4.60
52wk Low:0.5231
Shares:84.77M
Float Shares:67.15M
Volume Ratio:1.86
T/O Rate:7.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5119
EPS(LYR):-2.9606
ROE:-347.64%
ROA:-27.54%
PB:-2.67
PE(LYR):-0.34

Loading ...

Sutro Biopharma Chief Admin. Officer & GC David Pauling Reports Acquisition of Common Shares

Reuters
·
Oct 16

BRIEF-Sutro Biopharma says restructuring costs estimated at $4.1 million to $4.3 million - SEC filing

Reuters
·
Sep 30

BRIEF-Sutro Biopharma announces operational restructuring intended to extend cash runway

Reuters
·
Sep 30

Sutro Biopharma Inc - Restructuring Costs Estimated at $4.1 Mln to $4.3 Mln - SEC Filing

THOMSON REUTERS
·
Sep 30

Sutro Biopharma announces restructuring, workforce reduction of about 33%

TIPRANKS
·
Sep 30

Sutro Biopharma Inc - Announces Restructuring to Prioritize ADC Programs

THOMSON REUTERS
·
Sep 30

Sutro Biopharma Inc - Restructuring Expected to Extend Cash Runway Into Mid-2027

THOMSON REUTERS
·
Sep 30

Sutro Biopharma Inc - Restructuring to Result in Workforce Reduction of One-Third of Employees

THOMSON REUTERS
·
Sep 30

Sutro Biopharma Inc - on Track to Advance Stro-004 Into Clinic This Year, Data Expected 2026

THOMSON REUTERS
·
Sep 30

Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027

Reuters
·
Sep 30

Sutro Biopharma Inc : Jefferies Cuts Target Price to $4 From $7

THOMSON REUTERS
·
Sep 09

Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Sutro Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Aug 09

Sutro Biopharma Q2 EPS $(0.14) Beats $(0.45) Estimate, Sales $63.74M Beat $14.35M Estimate

Benzinga
·
Aug 08

BRIEF-Sutro Biopharma Q2 Revenue USD 63.745 Million

Reuters
·
Aug 08

Sutro Biopharma Q2 Basic EPS USD -0.14

THOMSON REUTERS
·
Aug 08

Sutro Biopharma Inc - Reports $18.4 Mln in Restructuring Costs for Q2 2025

THOMSON REUTERS
·
Aug 08

Sutro Biopharma: Will Continue to Recognize Restructuring Costs for Deprioritization of Luvelta Program ,to Recognize a Significant Portion in 2025

THOMSON REUTERS
·
Aug 08

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

GlobeNewswire
·
Aug 08

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

GlobeNewswire
·
Jul 22